Homologous recombination deficiency in primary ER-positive and HER2-negative breast cancer.

Clinically, HRD status was not significantly associated with patient outcomes after adjuvant systemic therapy, although patients with HRD tumors treated with endocrine therapy alone showed a trend toward poorer outcomes.

also in 53,322 other papers

While HRD status was not statistically associated with differences in patient outcome for patients treated with combined chemotherapy and endocrine therapy, a nonsignificant trend of poorer outcome for patients with HRD tumors was observed for patients treated with adjuvant endocrine therapy only.

also in 5,406 other papers